室间隔介入治疗肥厚型梗阻性心肌病的研究进展

Research advances in ventricular septal intervention in hypertrophic obstructive cardiomyopathy

肥厚型心肌病(HCM)是一种并非完全因心脏负荷异常引起的心室壁增厚疾病。尽管HCM是一种常见的心血管疾病,但却缺乏大规模的随机对照临床研究[1]。大约70%的HCM患者存在左室流出道梗阻(LVOTO),LVOTO是决定临床症状,如气短、胸痛、心悸和晕厥的一个重要因素;另外,无论是采取药物治疗还是室间隔切除术或室间隔介入治疗,LVOTO都是长期以来治疗的靶点之一。现将室间隔介入治疗肥厚型梗阻性心肌病(HOCM)的研究进展综述如下。

Hypertrophic cardiomyopathy （HCM） is defined by the presence of increased left ventricular （LV） wall thickness that is not solely explained by abnormal loading conditions. Although HCM is one type of common cardiovascular diseases, it lacks large-scale randomized controlled clinical studies. Almost 70% of HCM patients present with left ventricular outflow tract obstruction （LVOTO）, an important clinical decisive factor for symptoms such as dyspnea, chest pain, palpitation, and syncope. LVOTO is one of the therapy targets for either drug therapy or invasive therapy including ventricular septum resection or ventricular septal intervention such as anhydrous alcohol septurn ablation （ASA）. This article will review the research advances in ventricular septal intervention in HCM.